Patents Examined by Patrick T. Lewis
  • Method for treating cancer with combination therapy
    Patent number: 10946000
    Abstract: Provided are methods for treating cancer in a patient by administering at least one antibiotic selected from the group consisting of clofazimine, rifabutin and clarithromycin, in combination with an aryladamantane compound. In an embodiment, the aryladamantane compound is [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide], or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: March 16, 2021
    Assignee: RedHill Biopharma Ltd.
    Inventors: Reza Fathi, Dror Ben-Asher, Danielle Abramson
  • Pyrrolopyrimidine nucleosides and analogs thereof
    Patent number: 10941175
    Abstract: The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein Rc and A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: March 9, 2021
    Assignees: Chimerix, Inc., The Regents of the University of Michigan
    Inventors: John Henry Bougher, III, Ramamurty V S Changalvala, Aaron Leigh Downey, John C. Drach, Ernest Randall Lanier, Jr., Andrew Louis McIver, Bradley David Robertson, Dean Wallace Selleseth, Phiroze Behram Sethna, Leroy Townsend, Roy W. Ware
  • TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
    Patent number: 10933077
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: March 2, 2021
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Peter Wipf, Matthew D. Neal, Chhinder P. Sodhi, David J. Hackam
  • B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
    Patent number: 10934322
    Abstract: The present disclosure provides nicotinate/nicotinamide riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, and synthetic processes for the preparation thereof.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: March 2, 2021
    Assignees: ChromaDex Inc., The Queen's University of Belfast
    Inventors: Marie Eugenie Migaud, Philip Redpath, Kerri Crossey, Richard Cunningham, Ryan Dellinger, Troy Rhonemus, Sylesh Venkataraman, Brian Nettles
  • Isolation of nucleic acids
    Patent number: 10934539
    Abstract: Methods of isolating nucleic acids comprising DNA from biological material are disclosed. The methods comprise a lysis step using an aqueous composition which comprises lithium at a concentration of 0.05 to 1.0M, a chelating agent, and a surfactant to produce a lysed composition. The lysed composition is treated with a solid support that is capable of immobilising DNA in the presence of a dissolved chaotropic agent at a concentration of 0.05 to 2M and 25% to 60% by volume of a C1-3 alkanol. The support is then washed with a first wash solution containing lithium dissolved in a C1-3 alkanol. Subsequently, the support is washed with a liquid comprising at least 80% by volume of a C1-3 alkanol. The nucleic acid comprising DNA is then eluted from the support.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: March 2, 2021
    Assignee: RevoluGen Limited
    Inventors: Stephen John Minter, Georgios Patsos
  • Compositions and methods for reverse automated nucleic acid synthesis
    Patent number: 10927140
    Abstract: Methods for reverse automated nucleic acid synthesis, and 5?-H-phosphonates suitable for use in the same, as well as methods for making 5?-H-phosphonates, are described.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: February 23, 2021
    Assignee: The University of Toledo
    Inventors: Matthew Ellis, Amanda Bryant-Friedrich
  • Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
    Patent number: 10925866
    Abstract: The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: February 23, 2021
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, David J. Lockhart
  • Administration of nicotinamide mononucleotide in the treatment of disease
    Patent number: 10925888
    Abstract: Disclosed are methods and compositions related to methods of treating, ameliorating, mitigating, slowing, arresting, preventing or reversing various diseases and conditions, including age-related obesity, age-related increases in blood lipid levels, age-related decreases in insulin sensitivity, age-related decreases in memory function, and age-related changes in eye function such as macular degeneration. The methods comprise administering nicotinamide mononucleotide (NMN) to a subject. In some embodiments, the administration can be oral administration. Also disclosed are pharmaceutical compositions comprising NMN.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: February 23, 2021
    Assignee: Washington University
    Inventors: Shin-ichiro Imai, Rajendra Apte
  • Substituted nucleoside analogues for use as PRMT5 inhibitors
    Patent number: 10898504
    Abstract: The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: January 26, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Didier Jean-Claude Berthelot, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Arnodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Parade, Wim Bert Griet Schepens, Brian Christopher Shook, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye, Weimei Sun, Tongfei Wu, Lieven Meerpoel
  • Nucleoside phosphate compound and preparation method and use thereof
    Patent number: 10899786
    Abstract: Provided in the present invention are a compound of Formula (I), a pharmaceutical composition comprising the same, a method for preparing the same, and use thereof as a NS5B polymerase inhibitor, a DNA polymerase inhibitor or a reverse transcriptase inhibitor for the prevention or treatment of viral diseases or cancers.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: January 26, 2021
    Assignee: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Jiaqiang Cai, Shuai Song, Qiang Tian, Yitao Zhang, Haitao Huang, Guoqing Zhong, Wei Zhong, Yongjia Hao, Mingliang Zhao, Hong Zeng, Hongmei Song, Xin Zhou, Yao Liu, Yuting Tan, Lichun Wang, Jingyi Wang
  • Ester of aminoglycan and uses thereof
    Patent number: 10889608
    Abstract: A new biomaterial is disclosed. The biomaterial is prepared by mixing glycosaminoglycan with a phosphoric acid, phosphate ester, or salt or derivative thereof under the action of a catalyst in a liquid reaction medium at a pH of 2.1 to 4.9. The obtained material is capable of enhancing the immunological resistance in human and in animals, treating diseases in human and in animals caused by viruses or bacteria, strengthening the anti-stress ability of animals, improving the appetite of animals, promoting the growth of animals, inhibiting the growth of tumor, lowering blood fat level, as well as preventing and treating viral diseases in plants.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: January 12, 2021
    Assignee: CHENGDU AULI ECOLOGICAL TECHNOLOGY DEVELOPMENT CO., LTD.
    Inventor: Yong Huang
  • Application of a phillyrin/phillygeninin composition in preparing a medicine or health care product for alleviating or/and treating viral diseases, and medicine or health care product for treating viral diseases
    Patent number: 10881679
    Abstract: The present invention discloses a composition of phillyrin and phillygeninin in the preparation of drugs for alleviating or/and treating viral diseases. Experiments prove that the composition of phillyrin and phillygeninin has significant treatment effects on viral influenza and pneumonia, as well as on respiratory syncytial viruses, enteroviruses, herpes zoster simplex viruses, Coxsackie viruses, and the like. This composition is characterized by quick action and less toxic and side effects, and thus is an antiviral drug and health product with safety, high efficiency, stability and simple preparation process, and is suitable for industrial production and easy to promote. The present invention provides a drug, health product and raw material for preventing and treating various viral diseases.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: January 5, 2021
    Inventor: Li Fu
  • Purine nucleotide derivatives
    Patent number: 10882861
    Abstract: The present invention provides a compound having the structure:
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: January 5, 2021
    Assignee: The Research Foundation for the State University of New York
    Inventor: Mark Lukin
  • Anthranilyl-adenosinemonosulfamate analogs and uses thereof
    Patent number: 10874686
    Abstract: Provided herein are compounds of Formula (I) and pharmaceuticals acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, and prodrugs thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment and/or of an infectious disease (e.g., bacterial infection (e.g., P. aeruginosa infection).
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: December 29, 2020
    Assignees: Memorial Sloan-Kettering Cancer Center, The General Hospital Corporation, East Carolina University
    Inventors: Derek Shieh Tan, Cheng Ji, Indrajeet Sharma, Debarshi Pratihar, James P. Coleman, Everett C. Pesci, Laurence G. Rahme
  • N4-hydroxycytidine and derivatives and anti-viral uses related thereto
    Patent number: 10874683
    Abstract: This disclosure relates to certain N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of a Zika virus infection.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: December 29, 2020
    Assignee: Emory University
    Inventors: George R. Painter, David B. Guthrie, Gregory R. Bluemling, Michael R. Natchus
  • Highly active compounds against COVID-19
    Patent number: 10874687
    Abstract: The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: December 29, 2020
    Assignee: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • Oligomeric compounds comprising ?-?-constrained nucleic acid
    Patent number: 10865413
    Abstract: The present disclosure provides oligomeric compounds comprising at least one ?-?-constrained nucleic acid as provided herein. More particularly, the ?-?-constrained nucleic acid provided herein comprise an optionally modified nucleoside with a phosphorus containing constrained internucleoside linkage such as for example a cyclic phosphate internucleoside linkage. The ?-?-constrained nucleic acid provided herein are expected to be useful for enhancing one or more properties of oligomeric compounds they are incorporated into such as for example nuclease resistance. In certain embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: December 15, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Michael Oestergaard, Eric E. Swayze, Punit P. Seth
  • Compositions and methods for treating retinal degradation
    Patent number: 10864212
    Abstract: The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: December 15, 2020
    Assignee: University of Kentucky Research Foundation
    Inventors: Jayakrishna Ambati, Benjamin Fowler
  • Method of treating bacterial infections
    Patent number: 10828316
    Abstract: The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be trimethoprim or a compound comprising trimethoprim, such as trimethoprim-sulfa.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: November 10, 2020
    Assignee: ULTUPHARMA AB
    Inventors: Bo Öberg, Anders Broberg, Bengt Guss, Jolanta Levenfors, Joakim Bjerketorp, Christina Nord
  • Method of treating bacterial infections
    Patent number: 10828317
    Abstract: The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be iclaprim; trimethoprim; or a compound comprising trimethoprim, such as trimethoprim-sulfa.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: November 10, 2020
    Assignee: Ultupharma AB
    Inventors: Bo Öberg, Anders Broberg, Bengt Guss, Jolanta Levenfors, Joakim Bjerketorp, Christina Nord